Cision PR Newswire, Author at World Lifestyler

No Result

View All Result

WORLD LIFESTYLER

No Result

View All Result

Home Author

Cision PR Newswire

Press Releases

VolitionRx Announces Pricing of $4.6 Million Public Offering

June 7, 2026

Press Releases - Lifestyle

Once-Weekly CagriSema (Amylin-Semaglutide) Combination Injection More Effective than Standalone Medications

June 7, 2026

Press Releases - Lifestyle

Novo Nordisk’s CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026

June 7, 2026

Press Releases - Lifestyle

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

June 7, 2026

Press Releases - Lifestyle

Lipid-Lowering Medications Demonstrate Cardiometabolic Benefits in Populations with High-Risk Diabetes

June 7, 2026

Press Releases - Lifestyle

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

June 7, 2026

Press Releases - Lifestyle

Once-Weekly Drug Demonstrates Promising Dual Benefits in Obesity and Metabolic Health

June 7, 2026

Press Releases - Lifestyle

Bronstein, Gewirtz & Grossman LLC Urges Badger Meter, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

June 7, 2026

Press Releases - Lifestyle

Bronstein, Gewirtz & Grossman LLC Urges GeneDx Holdings Corp. Investors to Act: Class Action Filed Alleging Investor Harm

June 7, 2026

Press Releases - Lifestyle

Lilly’s Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause

June 7, 2026

Page 776 of 3687 Prev 1 … 775 776 777 … 3,687 Next

No Result

View All Result

Home

Cision PR Newswire

VolitionRx Announces Pricing of $4.6 Million Public Offering

Once-Weekly CagriSema (Amylin-Semaglutide) Combination Injection More Effective than Standalone Medications

Novo Nordisk’s CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

Lipid-Lowering Medications Demonstrate Cardiometabolic Benefits in Populations with High-Risk Diabetes

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

Once-Weekly Drug Demonstrates Promising Dual Benefits in Obesity and Metabolic Health

Bronstein, Gewirtz & Grossman LLC Urges Badger Meter, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Bronstein, Gewirtz & Grossman LLC Urges GeneDx Holdings Corp. Investors to Act: Class Action Filed Alleging Investor Harm

Lilly’s Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause

Recommended

Bright Eye Clinic Achieves Government Accreditation Amid Korea’s Medical Tourism Growth

TLC Jet Partners with American Airlines to Bring Exclusive Rewards and Seamless Travel Flexibility to Private Jet Clients

Popular News

BC Token Hits Record $0.01561 as BC Engine Expands Utility Across BC.GAME

GAC International Reaches 30 Million Fastest, Cementing Its “First Growth Curve”

Paratus Energy: Receipt of Competition Clearance for the Sale of Fontis

Moët Hennessy and Formula 1® unveil The Out Lap: the world’s first moving fine dining experience on a Formula 1 circuit

MM Art Indices Found Global Art Market Shows Signs of Synchronized Recovery in Spring 2026 Auctions After Post-Pandemic Correction

Connect with us

About & Contact

Explore Content

Legal & Privacy

Tiny Media Brands